PMID- 24116271
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20131011
LR  - 20211021
IS  - 1976-9148 (Print)
IS  - 2005-4483 (Electronic)
IS  - 1976-9148 (Linking)
VI  - 20
IP  - 1
DP  - 2012 Jan
TI  - Oroxylin A Induces BDNF Expression on Cortical Neurons through Adenosine A2A 
      Receptor Stimulation: A Possible Role in Neuroprotection.
PG  - 27-35
LID - 10.4062/biomolther.2012.20.1.027 [doi]
AB  - Oroxylin A is a flavone isolated from a medicinal herb reported to be effective 
      in reducing the inflammatory and oxidative stresses. It also modulates the 
      production of brain derived neurotrophic factor (BDNF) in cortical neurons by the 
      transactivation of cAMP response element-binding protein (CREB). As a 
      neurotrophin, BDNF plays roles in neuronal development, differentiation, 
      synaptogenesis, and neural protection from the harmful stimuli. Adenosine A2A 
      receptor colocalized with BDNF in brain and the functional interaction between 
      A2A receptor stimulation and BDNF action has been suggested. In this study, we 
      investigated the possibility that oroxylin A modulates BDNF production in 
      cortical neuron through the regulation of A2A receptor system. As ex-pected, 
      CGS21680 (A2A receptor agonist) induced BDNF expression and release, however, an 
      antagonist, ZM241385, prevented oroxylin A-induced increase in BDNF production. 
      Oroxylin A activated the PI3K-Akt-GSK-3beta signaling pathway, which is inhibited by 
      ZM241385 and the blockade of the signaling pathway abolished the increase in BDNF 
      production. The physiological roles of oroxylin A-induced BDNF production were 
      demonstrated by the increased neurite extension as well as synapse formation from 
      neurons. Overall, oroxylin A might regulate BDNF production in cortical neuron 
      through A2A receptor stimulation, which promotes cellular survival, synapse 
      formation and neurite extension.
FAU - Jeon, Se Jin
AU  - Jeon SJ
AD  - Department of Pharmacology, College of Pharmacy and Research Institute of 
      Pharmaceutical Sciences, Seoul National University, Seoul 151-742 ; Neuroscience 
      Research Center, Institute for Advanced Biomedical Sciences.
FAU - Bak, Haerang
AU  - Bak H
FAU - Seo, Jungeun
AU  - Seo J
FAU - Han, So Min
AU  - Han SM
FAU - Lee, Sung Hoon
AU  - Lee SH
FAU - Han, Seol-Heui
AU  - Han SH
FAU - Kwon, Kyoung Ja
AU  - Kwon KJ
FAU - Ryu, Jong Hoon
AU  - Ryu JH
FAU - Cheong, Jae Hoon
AU  - Cheong JH
FAU - Ko, Kwang Ho
AU  - Ko KH
FAU - Yang, Sung-Il
AU  - Yang SI
FAU - Choi, Ji Woong
AU  - Choi JW
FAU - Park, Seung Hwa
AU  - Park SH
FAU - Shin, Chan Young
AU  - Shin CY
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Biomol Ther (Seoul)
JT  - Biomolecules & therapeutics
JID - 101472832
PMC - PMC3792198
OTO - NOTNLM
OT  - Adenosine A2A receptor
OT  - BDNF
OT  - CGS21680
OT  - CREB
OT  - Oroxylin A
OT  - ZM241385
EDAT- 2012/01/01 00:00
MHDA- 2012/01/01 00:01
PMCR- 2012/01/01
CRDT- 2013/10/12 06:00
PHST- 2011/08/24 00:00 [received]
PHST- 2011/10/26 00:00 [revised]
PHST- 2011/11/02 00:00 [accepted]
PHST- 2013/10/12 06:00 [entrez]
PHST- 2012/01/01 00:00 [pubmed]
PHST- 2012/01/01 00:01 [medline]
PHST- 2012/01/01 00:00 [pmc-release]
AID - ooomb4-20-27 [pii]
AID - 10.4062/biomolther.2012.20.1.027 [doi]
PST - ppublish
SO  - Biomol Ther (Seoul). 2012 Jan;20(1):27-35. doi: 10.4062/biomolther.2012.20.1.027.